Peers of Agios Pharmaceuticals Inc (AGIO)
Side-by-side comparison
Health Care · Biotechnology
Enterprise value divided by trailing twelve-month revenue. A capital-structure-neutral sales valuation metric.
Latest EV/Sales
9.48x
As of Oct 9, 2026
Beyond EV/Sales, the valuation view includes forward multiples, EV ratios, cash flow yields, and multi-year chart history for further research.
| Date | EV/Sales |
|---|---|
| Oct 9, 2026 | 9.48x |
| Oct 8, 2026 | 9.54x |
| Oct 7, 2026 | 9.46x |
| Oct 6, 2026 | 9.41x |
| Oct 5, 2026 | 9.13x |
| Oct 2, 2026 | 9.46x |
| Oct 1, 2026 | 9.88x |
| Sep 30, 2026 | 10.34x |
EV/Sales = Enterprise Value / Revenue (TTM). Enterprise Value = Market Cap + Total Debt − (Cash & Short-Term Investments + Long-Term Investments).
EV/Sales is particularly useful in M&A analysis and for companies with significant debt.
Read the general EV/Sales definition, formula, and analyst usage guide.
EV/Sales guideInformational research only; not personalized advice. Values reflect the latest available data on Chartloom and may differ from other sources.
Side-by-side comparison